Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876305 | 1.00 | METAP1 (0.49) | METAP1METAP2SIGMAR1SMYD3DPP7 | |
| SCHEMBL6876886 | 1.00 | METAP1 (0.49) | METAP1METAP2SIGMAR1SMYD3DPP7 | |
| SCHEMBL6875880 | 1.00 | METAP1 (0.49) | METAP1METAP2SIGMAR1SMYD3DPP7 | |
| Hydrochloric Acid SCHEMBL742741 | 0.98 | METAP1 (0.48) | METAP1METAP2SIGMAR1SMYD3DPP7 | |
| Hydrochloric Acid SCHEMBL742742 | 0.98 | METAP1 (0.48) | METAP1METAP2SIGMAR1SMYD3DPP7 | |
| SCHEMBL8006760 | 0.94 | SIGMAR1 (0.51) | METAP1METAP2SIGMAR1EPHX1 | |
| SCHEMBL8492486 | 0.94 | SIGMAR1 (0.51) | METAP1METAP2SIGMAR1EPHX1 | |
| SCHEMBL12829172 | 0.92 | SIGMAR1 (0.53) | METAP2SIGMAR1EPHX1 | |
| SCHEMBL329101 | 0.90 | SMYD3 (0.43) | METAP1METAP2SIGMAR1SMYD3LMNA | |
| SCHEMBL3045972 | 0.90 | SMYD3 (0.43) | METAP1METAP2SIGMAR1SMYD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101242816-B | Hcv inhibitors | VIROBAY INC | 2012-10-31 | — | — | CN | disclosed |
| EP-2134739-B1 | SULFUR COMPOUNDS AS INHIIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7816326-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2134739-A2 | SULFUR COMPOUNDS AS INHIIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7485625-B2 | Inhibitors of hepatitis C virus NS3/NS4a serine protease | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2008124148-A2 | SULFUR COMPOUNDS AS INHIIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| CN-101242816-A | HCV inhibitors | VIROBAY INC (US) | 2008-08-13 | — | — | CN | disclosed |
| US-20070197448-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197448-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | PRSS1, PRSS3, HPN | METAP1 71/4885METAP2 175/4885SIGMAR1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.